64369-79-5

Usage

Uses

Used in Pharmaceutical Industry:
4-[(Methylsulfonyl)oxy]-benzeneacetic acid is used as an anti-inflammatory agent for the treatment of various inflammatory conditions. It is particularly beneficial for conditions such as arthritis, menstrual cramps, and other disorders characterized by inflammation. Its mechanism of action involves the inhibition of prostaglandin production, thereby reducing inflammation and associated symptoms.
However, similar to other NSAIDs, 4-[(Methylsulfonyl)oxy]-benzeneacetic acid may also carry the risk of adverse effects. Therefore, its use should be carefully considered and monitored under medical supervision to ensure safety and efficacy.
Furthermore, the compound holds promise for further research and development in the field of pharmacology. Continued investigation into its properties and potential applications may lead to the discovery of new therapeutic uses and advancements in the treatment of inflammatory conditions.

InChI:InChI=1/C9H10O5S/c1-15(12,13)14-8-4-2-7(3-5-8)6-9(10)11/h2-5H,6H2,1H3,(H,10,11)

Upstream product

• 539814-10-3 4-[(methoxycarbonyl)methyl]phenyl mesylate 
• 156-38-7 4-hydroxyphenylacetate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1055303-13-3 4-methanesulfonyloxy-benzoic acid 4-{2-carboxy-2-[2-(4-fluoro-phenyl)-ethylsulfanyl]-ethyl}-benzyl ester 
• 1055304-23-8 C₂₈H₂₆Cl₃FO₇S₂ 

Relevant academic research and scientific papers

PdII-Catalyzed methoxylation of C(sp3)-H bonds adjacent to benzoxazoles and benzothiazoles

The Pd(OAc)2/PhI(OAc)2 catalyst system promotes the highly regioselective dehydrogenative methoxylation of a C(sp3)-H bond adjacent to benzoxazole and benzothiazole rings. The title transformation constitutes the first example of a Pd-catalyzed C(sp3)-H activating methoxylation at the proximal-selective α-position with regard to a directing auxiliary and provides expedient access to an important class of azole-decorated methyl ethers (up to 90% isolated yield). The synthetic practicality of the methodology was demonstrated by achieving α-methoxyacetic acids via the elimination of the benzoxazole auxiliaries and by obtaining the precursor of an O-methylated Breslow intermediate.

2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.

Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.